Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Simple Scoring Tool to Estimate Risk of Hospitalization and Mortality in Ambulatory and Emergency Department Patients with COVID-19

View ORCID ProfileBrandon J. Webb, View ORCID ProfileNicholas M. Levin, Nancy Grisel, View ORCID ProfileSamuel M. Brown, View ORCID ProfileIthan D. Peltan, Emily S. Spivak, Mark Shah, Eddie Stenehjem, Joseph Bledsoe
doi: https://doi.org/10.1101/2021.02.22.21252171
Brandon J. Webb
1Intermountain Healthcare, Division of Infectious Diseases and Clinical Epidemiology, Salt Lake City, UT
2Stanford Medicine, Division of Infectious Diseases and Geographic Medicine, Palo Alto, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brandon J. Webb
  • For correspondence: Brandon.Webb@imail.org
Nicholas M. Levin
3University of Utah School of Medicine, Division of Emergency Medicine, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicholas M. Levin
Nancy Grisel
4Intermountain Healthcare, Enterprise Analytics, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel M. Brown
5Intermountain Medical Center and University of Utah, Division of Pulmonary and Critical Care Medicine, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Samuel M. Brown
Ithan D. Peltan
5Intermountain Medical Center and University of Utah, Division of Pulmonary and Critical Care Medicine, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ithan D. Peltan
Emily S. Spivak
6University of Utah School of Medicine, Division of Infectious Diseases, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Shah
7Intermountain Healthcare, Department of Emergency Medicine, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eddie Stenehjem
1Intermountain Healthcare, Division of Infectious Diseases and Clinical Epidemiology, Salt Lake City, UT
2Stanford Medicine, Division of Infectious Diseases and Geographic Medicine, Palo Alto, CA
8Intermountain Healthcare, Office of Patient Experience, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Bledsoe
7Intermountain Healthcare, Department of Emergency Medicine, Salt Lake City, UT
9Stanford Medicine, Department of Emergency Medicine, Palo Alto, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Accurate methods of identifying patients with COVID-19 who are at high risk of poor outcomes has become especially important with the advent of limited-availability therapies such as monoclonal antibodies. Here we describe development and validation of a simple but accurate scoring tool to classify risk of hospitalization and mortality.

Methods All consecutive patients testing positive for SARS-CoV-2 from March 25-October 1, 2020 within the Intermountain Healthcare system were included. The cohort was randomly divided into 70% derivation and 30% validation cohorts. A multivariable logistic regression model was fitted for 14-day hospitalization. The optimal model was then adapted to a simple, probabilistic score and applied to the validation cohort and evaluated for prediction of hospitalization and 28-day mortality.

Results 22,816 patients were included; mean age was 40 years, 50.1% were female and 44% identified as non-white race or Hispanic/Latinx ethnicity. 6.2% required hospitalization and 0.4% died. Criteria in the simple model included: age (0.5 points per decade); high-risk comorbidities (2 points each): diabetes mellitus, severe immunocompromised status and obesity (body mass index≥30); non-white race/Hispanic or Latinx ethnicity (2 points), and 1 point each for: male sex, dyspnea, hypertension, coronary artery disease, cardiac arrythmia, congestive heart failure, chronic kidney disease, chronic pulmonary disease, chronic liver disease, cerebrovascular disease, and chronic neurologic disease. In the derivation cohort (n=16,030) area under the receiver-operator characteristic curve (AUROC) was 0.82 (95% CI 0.81-0.84) for hospitalization and 0.91 (0.83-0.94) for 28-day mortality; in the validation cohort (n=6,786) AUROC for hospitalization was 0.8 (CI 0.78-0.82) and for mortality 0.8 (CI 0.69-0.9).

Conclusion A prediction score based on widely available patient attributes accurately risk stratifies patients with COVID-19 at the time of testing. Applications include patient selection for therapies targeted at preventing disease progression in non-hospitalized patients, including monoclonal antibodies. External validation in independent healthcare environments is needed.

Competing Interest Statement

Conflicts of Interest: IP reports salary support through a grant from the National Institutes of Health (U.S.A). SB reports salary support from the U.S. NIH, Centers for Disease Control and the Department of Defense; he also reports receiving support for chairing a data and safety monitoring board for a respiratory failure trial sponsored by Hamilton, effort paid to Intermountain for steering committee work for Faron Pharmaceuticals and Sedana Pharmaceuticals for ARDS work, support from Janssen for Influenza research, and royalties for books on religion and ethics from Oxford University Press/Brigham Young University. BW reports partial salary support from a U.S. Federal grant from AHRQ. ES receives partial salary support through grants from the Centers for Disease Control. At the time of submission, Intermountain Healthcare and the University of Utah have participated in COVID-19 trials sponsored by: Abbvie, Genentech, Gilead, Regeneron, Roche, and the U.S. National Institutes of Health ACTIV and PETAL clinical trials networks; several authors (BW, IP, JB, SB, ES) were site investigators on these trials but received no direct or indirect remuneration for their effort. ES, BJW, SMB and MS are members of the Utah crisis standards of care scarce medication committee.

Funding Statement

IP reports salary support through a grant from the National Institutes of Health (U.S.A). SB reports salary support from the U.S. NIH, Centers for Disease Control and the Department of Defense; he also reports receiving support for chairing a data and safety monitoring board for a respiratory failure trial sponsored by Hamilton, effort paid to Intermountain for steering committee work for Faron Pharmaceuticals and Sedana Pharmaceuticals for ARDS work, support from Janssen for Influenza research, and royalties for books on religion and ethics from Oxford University Press/Brigham Young University. BW reports partial salary support from a U.S. Federal grant from AHRQ. ES receives partial salary support through grants from the Centers for Disease Control. At the time of submission, Intermountain Healthcare and the University of Utah have participated in COVID-19 trials sponsored by: Abbvie, Genentech, Gilead, Regeneron, Roche, and the U.S. National Institutes of Health ACTIV and PETAL clinical trials networks; several authors (BW, IP, JB, SB, ES) were site investigators on these trials but received no direct or indirect remuneration for their effort. ES, BJW, SMB and MS are members of the Utah crisis standards of care scarce medication committee.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This analysis was approved by the Institutional Review Board at Intermountain Healthcare under #1051342.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

In order to protect patient privacy and comply with institutional data use policy, data used in this study are unavailable to upload to public servers. As required by the Intermountain Healthcare Institutional Review Board, data sharing agreement requests to access deidentified versions of the datasets generated and/or analyzed during the current study may be addressed to the Intermountain Office of Research (officeofresearch{at}imail.org)

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted February 23, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Simple Scoring Tool to Estimate Risk of Hospitalization and Mortality in Ambulatory and Emergency Department Patients with COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Simple Scoring Tool to Estimate Risk of Hospitalization and Mortality in Ambulatory and Emergency Department Patients with COVID-19
Brandon J. Webb, Nicholas M. Levin, Nancy Grisel, Samuel M. Brown, Ithan D. Peltan, Emily S. Spivak, Mark Shah, Eddie Stenehjem, Joseph Bledsoe
medRxiv 2021.02.22.21252171; doi: https://doi.org/10.1101/2021.02.22.21252171
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Simple Scoring Tool to Estimate Risk of Hospitalization and Mortality in Ambulatory and Emergency Department Patients with COVID-19
Brandon J. Webb, Nicholas M. Levin, Nancy Grisel, Samuel M. Brown, Ithan D. Peltan, Emily S. Spivak, Mark Shah, Eddie Stenehjem, Joseph Bledsoe
medRxiv 2021.02.22.21252171; doi: https://doi.org/10.1101/2021.02.22.21252171

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Emergency Medicine
Subject Areas
All Articles
  • Addiction Medicine (180)
  • Allergy and Immunology (435)
  • Anesthesia (99)
  • Cardiovascular Medicine (949)
  • Dentistry and Oral Medicine (178)
  • Dermatology (111)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (423)
  • Epidemiology (9017)
  • Forensic Medicine (4)
  • Gastroenterology (422)
  • Genetic and Genomic Medicine (1963)
  • Geriatric Medicine (191)
  • Health Economics (405)
  • Health Informatics (1332)
  • Health Policy (662)
  • Health Systems and Quality Improvement (522)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10831)
  • Intensive Care and Critical Care Medicine (576)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (223)
  • Neurology (1842)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (357)
  • Occupational and Environmental Health (470)
  • Oncology (1006)
  • Ophthalmology (299)
  • Orthopedics (111)
  • Otolaryngology (184)
  • Pain Medicine (126)
  • Palliative Medicine (45)
  • Pathology (267)
  • Pediatrics (583)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1910)
  • Public and Global Health (4137)
  • Radiology and Imaging (678)
  • Rehabilitation Medicine and Physical Therapy (370)
  • Respiratory Medicine (551)
  • Rheumatology (226)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (110)
  • Urology (82)